Navigation Links
Karmanos Cancer Institute Researchers Provide New Hope for Breast Cancer Treatment
Date:4/22/2009

Abstract #5637

DENVER, April 22 /PRNewswire-USNewswire/ -- Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented data today at the American Association for Cancer Research's 100th Annual Meeting 2009 that signifies exciting research advancements in the treatment of the more aggressive forms of breast cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO)

Researchers gave an oral presentation about compounds derived from an FDA-approved drug used for the treatment of alcoholism that could provide viable treatment options for breast cancer patients.

Angelika Burger, Ph.D., director of the Translational Research Laboratory at the Karmanos Cancer Institute and professor of Pharmacology at Wayne State University, served as principle investigator. Doctoral candidate Daniela Buac of Wayne State University School of Medicine gave the oral presentation.

Researchers from the Karmanos Cancer Institute and Wayne State University in Detroit, Cardiff University in Great Britain, and the Sunnybrook Research Institute in Toronto designed a series of compounds based on Disulfiram (DSF) and found that one of the compounds was more potent than DSF itself in inhibiting an enzyme that spurs the growth of breast cancers. More than 50 percent of invasive breast cancers have the presence of the enzyme that could be treated by the DSF-derived compound.

"DSF is a very safe drug," said Dr. Burger. "It could be given to cancer patients alone or in combination with standard therapies used to treat breast cancers."

Karmanos scientists are encouraging additional preclinical testing. They are building upon past research employing the use of DSF in fighting breast cancers.

"Another colleague at Karmanos has worked with this drug too and we already have animal data showing that DSF treatments work," said Dr. Burger. "I anticipate that we'll collaborate with our breast cancer clinicians to translate the findings into clinical trials."

Earlier in the week, Karmanos Cancer Institute researchers presented a poster that showed pre-clinical, experimental drug combinations provide real hope to those dealing with the more dangerous, triple-negative forms of breast cancer.

"There are many drugs that are being studied," she said. "Down the road, they might be useful drugs for the treatment of breast cancer. I'm very excited about the research."

Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 40 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. For more information call 1-800-KARMANOS or go to www.karmanos.org.


'/>"/>
SOURCE Karmanos Cancer Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Komen Detroit and the Karmanos Cancer Institute Applaud Introduction of Bipartisan Cancer Alert Act
2. Karmanos Cancer Institute Announces Interim Leadership
3. Andre Konski, M.D., M.B.A., Accepts Radiation Oncology Position at Wayne State University and the Karmanos Cancer Institute
4. Danialle Karmanos Work It Out Names Tracey Secco as Director of Operations
5. Karmanos Cancer Institute Seeks Breast Cancer Patients to Participate in a New Drug Trial
6. Danialle Karmanos Work It Out (DKWIO) Site Earns Recognition for Web Excellence
7. Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan
8. J.P. McCarthy Fund Grants $250,000 to Karmanos Cancer Institute
9. Karmanos Cancer Center Partners With Meadowbrook to Expand Outreach and Access for Cancer Services
10. Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component
11. McCarty Cancer Foundation Awards $50,000 Grant for Myeloma Research Program at Karmanos Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology: